Share on LinkedInShare on LinkedIn

ARTICLE · 02 JULY 2026

Life Sciences Patents Monthly Roundup—June 2026

A&O Shearman
A&O Shearman
Contributor

A&O Shearman

Introducing A&O Shearman Unparalleled global depth for a changing world. Today more than ever,...

View firm profile
Explore more from A&O Shearman

This monthly roundup examines critical patent and regulatory developments across multiple jurisdictions, including landmark UPC rulings on injunction compliance and patient-interest defenses, CJEU questions on SPC manufacturing waivers, and a unanimous U.S. Supreme Court decision on generic drug labeling and induced infringement.

GlobalIntellectual Property

Welcome to the June edition of our Life Sciences Patents Monthly Roundup, where our global A&O Shearman team highlights key developments shaping the patent and regulatory landscape. In this month’s edition, we cover a range of developments across the UPC, the CJEU, Germany, France, and the United States.

At the Unified Patent Court (UPC), the Hamburg Local Division rules that defendants must take effective steps to ensure compliance with injunctions by third-party service providers and platforms acting on their behalf. The Düsseldorf Local Division confirms that a patentee need not practice its own invention to obtain injunctive relief and rejected a patient-interest defense in circumstances where alternative products were available on the market.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from